Cemiplimab launch time and progress in China

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor that has received widespread attention around the world in recent years. It blocks the PD-1 pathway to enhance the ability of T cells to recognize and kill tumors, and is used in the treatment of a variety of malignant tumors. As an anti-PD-1 monoclonal antibody jointly developed by Regeneron and Sanofi, Cemiplimab has been approved by the FDA and EMA in Europe and the United States. Its main indications include patients with advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, and some non-small cell lung cancer. However, in the Chinese market, the drug has not yet been officially launched for sale.

According to overseas public information, cimepilimab received rapid approval from the US FDA as early as2018, and has gradually expanded its indications. In contrast, China's introduction progress is relatively lagging behind, and may still be in the application and clinical trial stages. Some multinational pharmaceutical companies usually decide their drug launch strategy in China based on market size, competition landscape and local clinical research needs. Judging from the current situation, although Cemiplimab has a good reputation around the world, as a number of PD-1 inhibitors have been approved in China, such as sintilimab, camrelizumab, toripalimab, etc., its market space and clinical positioning still need to be further evaluated.

For Chinese patients, this means that they can only rely on international drug introduction channels or overseas medical resources to obtain cimepilimab treatment, and cannot directly purchase drugs in local pharmacies or hospitals. Nonetheless, as the introduction of global innovative drugs into China continues to accelerate, Cemiplimab may still enter the country in the future, especially in some special indications that are not fully covered by domestic PD-1.

Generally speaking, the launch time of cimepilimab in China has not yet been determined, and there is currently no official sales channel. For patients, while waiting for the drug to enter the domestic market, they can explore alternatives with their doctors to avoid delays in treatment due to drug availability issues.

Reference materials:https://www.libtayohcp.com/